← Elevance Health overview

Elevance Health vs Centene: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Elevance Health Inc (ELV)

Q3 2026
▲2▼2

Elevance beats Q2 but Medicaid margin drag and CMS lawsuit weigh

  • Medicaid margin turns negative, exits planned Elevance's Medicaid business is losing money, with a full-year margin of about -1.75%. The company is exiting Washington D.C. and more markets over 12-18 months. This drags overall profit and makes the 2027 growth target uncertain, pushing the stock down.

    This is the core reason the stock fell after earnings and is the main new negative force.

  • Elevance sues CMS over $115M Medicare Advantage bonus Elevance is suing Medicare's agency for recalculating a rival's star ratings after the fact, costing Elevance $115 million in bonus payments. The lawsuit adds regulatory uncertainty and could delay or reduce future bonus money, weighing on the stock.

    This is a new legal and regulatory risk that directly affects a revenue source.

  • Q2 earnings beat and guidance raised Elevance reported Q2 adjusted earnings of $7.45 per share, about 20% above estimates, and raised full-year guidance to at least $27.00. Revenue also beat. This shows the core business is stronger than expected, which supports the stock price.

    This is the main positive new event that initially lifted the stock before the Medicaid concerns took over.

  • Strong cash flow and buybacks support shares Elevance generated $4.3 billion in operating cash flow last quarter, expects at least $5.5 billion this year, and is buying back stock and paying dividends. This steady return of cash can cushion the stock and signals confidence.

    This is a new capital-return update that provides a positive counterweight to the margin issues.

July 2026
▲2▼2

Elevance beats Q2 but Medicaid margin drag and CMS lawsuit weigh

  • Medicaid margin turns negative, exits planned Elevance's Medicaid business is losing money, with a full-year margin of about -1.75%. The company is exiting Washington D.C. and more markets over 12-18 months. This drags overall profit and makes the 2027 growth target uncertain, pushing the stock down.

    This is the core reason the stock fell after earnings and is the main new negative force.

  • Elevance sues CMS over $115M Medicare Advantage bonus Elevance is suing Medicare's agency for recalculating a rival's star ratings after the fact, costing Elevance $115 million in bonus payments. The lawsuit adds regulatory uncertainty and could delay or reduce future bonus money, weighing on the stock.

    This is a new legal and regulatory risk that directly affects a revenue source.

  • Q2 earnings beat and guidance raised Elevance reported Q2 adjusted earnings of $7.45 per share, about 20% above estimates, and raised full-year guidance to at least $27.00. Revenue also beat. This shows the core business is stronger than expected, which supports the stock price.

    This is the main positive new event that initially lifted the stock before the Medicaid concerns took over.

  • Strong cash flow and buybacks support shares Elevance generated $4.3 billion in operating cash flow last quarter, expects at least $5.5 billion this year, and is buying back stock and paying dividends. This steady return of cash can cushion the stock and signals confidence.

    This is a new capital-return update that provides a positive counterweight to the margin issues.

Latest
▲2▼2

Elevance beats Q2 but Medicaid margin drag and CMS lawsuit weigh

  • Medicaid margin turns negative, exits planned Elevance's Medicaid business is losing money, with a full-year margin of about -1.75%. The company is exiting Washington D.C. and more markets over 12-18 months. This drags overall profit and makes the 2027 growth target uncertain, pushing the stock down.

    This is the core reason the stock fell after earnings and is the main new negative force.

  • Elevance sues CMS over $115M Medicare Advantage bonus Elevance is suing Medicare's agency for recalculating a rival's star ratings after the fact, costing Elevance $115 million in bonus payments. The lawsuit adds regulatory uncertainty and could delay or reduce future bonus money, weighing on the stock.

    This is a new legal and regulatory risk that directly affects a revenue source.

  • Q2 earnings beat and guidance raised Elevance reported Q2 adjusted earnings of $7.45 per share, about 20% above estimates, and raised full-year guidance to at least $27.00. Revenue also beat. This shows the core business is stronger than expected, which supports the stock price.

    This is the main positive new event that initially lifted the stock before the Medicaid concerns took over.

  • Strong cash flow and buybacks support shares Elevance generated $4.3 billion in operating cash flow last quarter, expects at least $5.5 billion this year, and is buying back stock and paying dividends. This steady return of cash can cushion the stock and signals confidence.

    This is a new capital-return update that provides a positive counterweight to the margin issues.

Q2 2026
▲3▼1

Elevance pushes tech and housing to offset regulatory and cost risks

  • Health OS cuts prior authorization denials by 61% Elevance's Health OS platform reduced prior authorization denials by 61% and sped up reviews, with over 30 health systems participating. This lowers administrative costs and improves efficiency, which can boost profit margins and support the stock price.

    This is a new operational improvement that directly lowers costs and supports earnings growth.

  • Carelon drives future earnings growth Carelon now makes up 36.3% of Elevance's revenue and uses AI to cut hospital readmissions by 20%. The company raised its 2026 profit guidance to at least $26.75 per share, showing confidence in this growth engine.

    Carelon's growing contribution and raised guidance are key positive drivers for future earnings.

  • CNSide deal expands covered lives to 45.4 million Elevance signed a national agreement with CNSide Diagnostics to offer a tumor cell test to about 45.4 million covered lives. This expands its service offerings and could attract more members, supporting revenue growth.

    New partnership expands covered lives and service portfolio, a direct demand driver.

  • No Surprises Act arbitration awards far exceed in-network rates An Elevance study found arbitration awards for planned procedures are often 50 times higher than in-network rates, raising costs. This could lead to regulatory scrutiny or policy changes that hurt insurers' profits.

    This highlights a regulatory and cost risk that could negatively impact Elevance's margins.

June 2026
▲3▼1

Elevance pushes tech and housing to offset regulatory and cost risks

  • Health OS cuts prior authorization denials by 61% Elevance's Health OS platform reduced prior authorization denials by 61% and sped up reviews, with over 30 health systems participating. This lowers administrative costs and improves efficiency, which can boost profit margins and support the stock price.

    This is a new operational improvement that directly lowers costs and supports earnings growth.

  • Carelon drives future earnings growth Carelon now makes up 36.3% of Elevance's revenue and uses AI to cut hospital readmissions by 20%. The company raised its 2026 profit guidance to at least $26.75 per share, showing confidence in this growth engine.

    Carelon's growing contribution and raised guidance are key positive drivers for future earnings.

  • CNSide deal expands covered lives to 45.4 million Elevance signed a national agreement with CNSide Diagnostics to offer a tumor cell test to about 45.4 million covered lives. This expands its service offerings and could attract more members, supporting revenue growth.

    New partnership expands covered lives and service portfolio, a direct demand driver.

  • No Surprises Act arbitration awards far exceed in-network rates An Elevance study found arbitration awards for planned procedures are often 50 times higher than in-network rates, raising costs. This could lead to regulatory scrutiny or policy changes that hurt insurers' profits.

    This highlights a regulatory and cost risk that could negatively impact Elevance's margins.

▲3▼1

Elevance pushes tech and housing to offset regulatory and cost risks

  • Health OS cuts prior authorization denials by 61% Elevance's Health OS platform reduced prior authorization denials by 61% and sped up reviews, with over 30 health systems participating. This lowers administrative costs and improves efficiency, which can boost profit margins and support the stock price.

    This is a new operational improvement that directly lowers costs and supports earnings growth.

  • Carelon drives future earnings growth Carelon now makes up 36.3% of Elevance's revenue and uses AI to cut hospital readmissions by 20%. The company raised its 2026 profit guidance to at least $26.75 per share, showing confidence in this growth engine.

    Carelon's growing contribution and raised guidance are key positive drivers for future earnings.

  • CNSide deal expands covered lives to 45.4 million Elevance signed a national agreement with CNSide Diagnostics to offer a tumor cell test to about 45.4 million covered lives. This expands its service offerings and could attract more members, supporting revenue growth.

    New partnership expands covered lives and service portfolio, a direct demand driver.

  • No Surprises Act arbitration awards far exceed in-network rates An Elevance study found arbitration awards for planned procedures are often 50 times higher than in-network rates, raising costs. This could lead to regulatory scrutiny or policy changes that hurt insurers' profits.

    This highlights a regulatory and cost risk that could negatively impact Elevance's margins.

Centene Corp (CNC)

Q3 2026
▲2▼1

Centene's profit recovery accelerates as costs ease and guidance jumps

  • Q2 earnings blow past estimates, 2026 profit outlook raised sharply Centene reported Q2 adjusted EPS of $2.51, crushing the $1.09 consensus, and raised full-year 2026 profit guidance to over $4.80 from $3.40. The medical loss ratio improved to 89.6% from 93%, showing costs are finally under control. This directly boosts the stock because it signals a faster-than-expected turnaround.

    This is the period's biggest new event and the main reason CNC is moving.

  • Medical cost trend stabilizes, easing two-year industry squeeze Oakmark and other funds noted that the unprecedented spike in medical costs is stabilizing or decelerating. Combined with better pricing and Centene's expense cuts, this points to a multi-year earnings recovery. For investors, it means the worst of the margin pressure may be over, supporting a higher stock price.

    Explains the fundamental force behind the profit rebound and why investors are more optimistic.

  • Trump administration ends Medicare Part D subsidy, raising 2027 premiums The administration is ending a $3.6 billion subsidy that helped insurers keep Part D premiums low. Three out of four enrollees will see higher monthly premiums in 2027, and Centene, as a top Part D insurer, faces reduced government payments and potential membership loss. This is a real counterweight that could pressure future profits.

    It is the main negative development this period and a genuine risk to the bullish story.

July 2026
▲2▼1

Centene's profit recovery accelerates as costs ease and guidance jumps

  • Q2 earnings blow past estimates, 2026 profit outlook raised sharply Centene reported Q2 adjusted EPS of $2.51, crushing the $1.09 consensus, and raised full-year 2026 profit guidance to over $4.80 from $3.40. The medical loss ratio improved to 89.6% from 93%, showing costs are finally under control. This directly boosts the stock because it signals a faster-than-expected turnaround.

    This is the period's biggest new event and the main reason CNC is moving.

  • Medical cost trend stabilizes, easing two-year industry squeeze Oakmark and other funds noted that the unprecedented spike in medical costs is stabilizing or decelerating. Combined with better pricing and Centene's expense cuts, this points to a multi-year earnings recovery. For investors, it means the worst of the margin pressure may be over, supporting a higher stock price.

    Explains the fundamental force behind the profit rebound and why investors are more optimistic.

  • Trump administration ends Medicare Part D subsidy, raising 2027 premiums The administration is ending a $3.6 billion subsidy that helped insurers keep Part D premiums low. Three out of four enrollees will see higher monthly premiums in 2027, and Centene, as a top Part D insurer, faces reduced government payments and potential membership loss. This is a real counterweight that could pressure future profits.

    It is the main negative development this period and a genuine risk to the bullish story.

Latest
▲2▼1

Centene's profit recovery accelerates as costs ease and guidance jumps

  • Q2 earnings blow past estimates, 2026 profit outlook raised sharply Centene reported Q2 adjusted EPS of $2.51, crushing the $1.09 consensus, and raised full-year 2026 profit guidance to over $4.80 from $3.40. The medical loss ratio improved to 89.6% from 93%, showing costs are finally under control. This directly boosts the stock because it signals a faster-than-expected turnaround.

    This is the period's biggest new event and the main reason CNC is moving.

  • Medical cost trend stabilizes, easing two-year industry squeeze Oakmark and other funds noted that the unprecedented spike in medical costs is stabilizing or decelerating. Combined with better pricing and Centene's expense cuts, this points to a multi-year earnings recovery. For investors, it means the worst of the margin pressure may be over, supporting a higher stock price.

    Explains the fundamental force behind the profit rebound and why investors are more optimistic.

  • Trump administration ends Medicare Part D subsidy, raising 2027 premiums The administration is ending a $3.6 billion subsidy that helped insurers keep Part D premiums low. Three out of four enrollees will see higher monthly premiums in 2027, and Centene, as a top Part D insurer, faces reduced government payments and potential membership loss. This is a real counterweight that could pressure future profits.

    It is the main negative development this period and a genuine risk to the bullish story.

Q2 2026
▲2▼2

Centene cuts costs, raises guidance, and secures Medicaid renewal

  • Buyouts and layoffs signal membership decline Centene launched buyouts for most of its 61,000 employees and warned of layoffs due to sharp membership declines in Medicaid and ACA. This cost-cutting reflects a shrinking business, which pressures the stock as investors worry about future revenue.

    This is a major new event that directly affects Centene's cost structure and signals underlying membership weakness.

  • UBS says AI gains may be competed away for insurers UBS analysts argue that AI efficiency gains for insurers like Centene are easily copied and will be competed away through pricing, limiting margin expansion. This tempers hopes that AI will significantly boost profits, weighing on the stock.

    This new analyst view challenges the bullish AI narrative for Centene and highlights a competitive risk.

  • Centene raises 2026 EPS guidance on strong Q1 Centene raised its 2026 adjusted EPS guidance to over $3.40 after Q1 EPS rose 16.2% to $3.37. Premium revenues grew 5.1% and Medicaid margin improved, showing better cost control and profitability, which supports a higher stock price.

    This is a new positive development that directly boosts earnings expectations and investor confidence.

  • Illinois Medicaid contract renewal secures revenue Centene's Meridian Health Plan won a four-year renewal for Illinois Medicaid, covering over 596,000 members. This preserves a steady stream of premium revenue and improves long-term earnings visibility, a positive for the stock.

    This new contract renewal reduces uncertainty and locks in a significant revenue source.

June 2026
▲2▼2

Centene cuts costs, raises guidance, and secures Medicaid renewal

  • Buyouts and layoffs signal membership decline Centene launched buyouts for most of its 61,000 employees and warned of layoffs due to sharp membership declines in Medicaid and ACA. This cost-cutting reflects a shrinking business, which pressures the stock as investors worry about future revenue.

    This is a major new event that directly affects Centene's cost structure and signals underlying membership weakness.

  • UBS says AI gains may be competed away for insurers UBS analysts argue that AI efficiency gains for insurers like Centene are easily copied and will be competed away through pricing, limiting margin expansion. This tempers hopes that AI will significantly boost profits, weighing on the stock.

    This new analyst view challenges the bullish AI narrative for Centene and highlights a competitive risk.

  • Centene raises 2026 EPS guidance on strong Q1 Centene raised its 2026 adjusted EPS guidance to over $3.40 after Q1 EPS rose 16.2% to $3.37. Premium revenues grew 5.1% and Medicaid margin improved, showing better cost control and profitability, which supports a higher stock price.

    This is a new positive development that directly boosts earnings expectations and investor confidence.

  • Illinois Medicaid contract renewal secures revenue Centene's Meridian Health Plan won a four-year renewal for Illinois Medicaid, covering over 596,000 members. This preserves a steady stream of premium revenue and improves long-term earnings visibility, a positive for the stock.

    This new contract renewal reduces uncertainty and locks in a significant revenue source.

▲2▼2

Centene cuts costs, raises guidance, and secures Medicaid renewal

  • Buyouts and layoffs signal membership decline Centene launched buyouts for most of its 61,000 employees and warned of layoffs due to sharp membership declines in Medicaid and ACA. This cost-cutting reflects a shrinking business, which pressures the stock as investors worry about future revenue.

    This is a major new event that directly affects Centene's cost structure and signals underlying membership weakness.

  • UBS says AI gains may be competed away for insurers UBS analysts argue that AI efficiency gains for insurers like Centene are easily copied and will be competed away through pricing, limiting margin expansion. This tempers hopes that AI will significantly boost profits, weighing on the stock.

    This new analyst view challenges the bullish AI narrative for Centene and highlights a competitive risk.

  • Centene raises 2026 EPS guidance on strong Q1 Centene raised its 2026 adjusted EPS guidance to over $3.40 after Q1 EPS rose 16.2% to $3.37. Premium revenues grew 5.1% and Medicaid margin improved, showing better cost control and profitability, which supports a higher stock price.

    This is a new positive development that directly boosts earnings expectations and investor confidence.

  • Illinois Medicaid contract renewal secures revenue Centene's Meridian Health Plan won a four-year renewal for Illinois Medicaid, covering over 596,000 members. This preserves a steady stream of premium revenue and improves long-term earnings visibility, a positive for the stock.

    This new contract renewal reduces uncertainty and locks in a significant revenue source.

© 2026 MarketIVWhy